Trials / Conditions / Therapy-Related Acute Myeloid Leukemia

Therapy-Related Acute Myeloid Leukemia

23 registered clinical trials studyying Therapy-Related Acute Myeloid Leukemia.

Status	Trial	Sponsor	Phase
Completed	VYxeoS Liposomal Italian Observational Study iN the Real Practice NCT06143839	Jazz Pharmaceuticals	—
Active Not Recruiting	CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old NCT04269213	Roswell Park Cancer Institute	Phase 2
Withdrawn	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898	Fred Hutchinson Cancer Center	Phase 2
Completed	TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia NCT04518345	Uma Borate	EARLY_Phase 1
Terminated	Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633	Rutgers, The State University of New Jersey	EARLY_Phase 1
Active Not Recruiting	Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting NCT04128501	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission NCT04062266	M.D. Anderson Cancer Center	Phase 2
Completed	A Post-Marketing Observational Study of VYXEOS™ NCT03526926	Jazz Pharmaceuticals	—
Active Not Recruiting	Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia NCT03330821	University of Southern California	Phase 1 / Phase 2
Active Not Recruiting	Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia NCT03009240	City of Hope Medical Center	Phase 1
Completed	Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia NCT03226418	University of Nebraska	Phase 2
Completed	Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia NCT02658487	Vanderbilt-Ingram Cancer Center	Phase 2
Completed	Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations NCT02323607	Bhavana Bhatnagar	Phase 1
Completed	Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Di NCT02397720	M.D. Anderson Cancer Center	Phase 2
Completed	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leuke NCT01904136	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignan NCT01823198	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Unknown	NK Cells in Cord Blood Transplantation NCT01619761	M.D. Anderson Cancer Center	Phase 1
Completed	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Terminated	Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplasti NCT01640301	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia NCT01420926	National Cancer Institute (NCI)	Phase 2
Completed	Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia NCT01253070	National Cancer Institute (NCI)	Phase 2
Completed	Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01238211	National Cancer Institute (NCI)	Phase 2
Completed	Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01130506	National Cancer Institute (NCI)	Phase 1